26 Aug, 2021 09:38 AM
SUDA enhances its Scientific Advisory Board (SAB) to gain expert guidance on the clinical development of allogenic cell therapies
Dr Reuben Benjamin, who leads the plasma cell disorder service an...read more
24 Aug, 2021 10:53 AM
SUDA grants an exclusive Licence for the rights to ZolpiMist® for commercialisation in Australia to STADA Pharmaceuticals, part of the international Pharmaceutical Company, STADA Group
SUDA t...read more
23 Aug, 2021 03:33 PM
SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, advises that Mitsubishi Tanabe Pha...read more
16 Aug, 2021 09:54 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, has entered into a Collaborative R...read more
02 Aug, 2021 09:15 AM
Dr Sandhya Buchanan joins SUDA to lead the technology transfer, manufacturing, and quality efforts for its newly acquired invariant Natural Killer T (iNKT) cell therapy platform.
Dr Buchanan has ...read more
26 Jul, 2021 10:13 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, today released its Appendix 4C for...read more
22 Jun, 2021 10:10 AM
SUDA Pharmaceuticals Ltd (ASX: SUD) is pleased to announce that the Company has received firm commitments for a capital raising by placing up to 96,163,997 ordinary shares to institutional and sophi...read more
18 Jun, 2021 10:22 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), today announces that it has signed a global, exclusive Licence Agreement with Imperial College London for a novel invariant Natural Killer T (iNKT) cell therapy ...read more
18 Jun, 2021 09:26 AM
The securities of Suda Pharmaceuticals Ltd (‘SUD’) will be placed in trading halt at the request of SUD, pending it releasing an announcement. Unless ASX decides otherwise, the securitie...read more
27 Apr, 2021 08:21 AM
SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, today released its Appendix 4C for the consolidated group for the third quarter of FY 2021.
Highlights
End of period c...read more
